Literature DB >> 19460788

Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.

N Aceto1, P Bertino, D Barbone, G Tassi, L Manzo, C Porta, L Mutti, G Gaudino.   

Abstract

Malignant mesothelioma is an asbestos-related, aggressive tumour, resistant to most anticancer therapies. Akt is a key mediator of mesothelioma cell survival and chemoresistance. This study aimed to clarify the mechanism by which taurolidine (TN), a known synthetic compound with antimicrobial and antineoplastic properties, leads to mesothelioma cell death. Apoptosis was studied by annexin V binding, cell cycle analysis, caspase-8 activation, poly(ADP-ribose) polymerase (PARP) cleavage and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling (TUNEL). Oxidative stress was measured by nitrite production and DNA oxidative damage. Protein expression and phosphorylation were evaluated by immunoprecipitation and immunoblotting. TN induces cell death of mesothelioma cells, but not of non-neoplastic human mesothelial cells. After TN treatment of mesothelioma cells, Akt but not extracellular signal-regulated kinase (Erk) 1/2 activity is inhibited a in time- and dose-dependent manner. Protein phosphatase (PP)1alpha and PP2A are activated several hours after drug addition. Apoptosis induced by TN is driven by oxidative stress and cell exposure to sulfydryl donors, such as glutathione monoethylester and l-N-acetylcysteine, significantly reduced pro-apoptotic effects and Akt inhibition. Conversely, expression of constitutively activated Akt did not affect cytoxicity elicited by TN, which retained its ability to inhibit the kinase. TN induces mesothelioma cell death via oxidative stress, accompanied by inhibition of Akt signalling. This provides a promising molecular rationale for TN as local treatment of malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460788     DOI: 10.1183/09031936.00102308

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.

Authors:  Ansgar M Chromik; Adrien Daigeler; Daniel Bulut; Annegret Flier; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Peter R Ritter; Ulrich Mittelkötter; Stephan A Hahn; Waldemar Uhl
Journal:  J Exp Clin Cancer Res       Date:  2010-03-07

2.  Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.

Authors:  Hui Wei; Hui-Liang Zhang; Jia-Zhao Xie; Dong-Li Meng; Xiao-Chuan Wang; Dan Ke; Ji Zeng; Rong Liu
Journal:  Curr Med Sci       Date:  2020-03-13

Review 3.  Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

Authors:  Michael Voronkov; Steven P Braithwaite; Jeffry B Stock
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

Review 4.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

5.  Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.

Authors:  Ansgar M Chromik; Stephan A Hahn; Adrien Daigeler; Annegret Flier; Daniel Bulut; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Dirk Weyhe; Ulrich Mittelkötter; Waldemar Uhl
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

6.  Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.

Authors:  Iza Denis; Laurent Cellerin; Marc Gregoire; Christophe Blanquart
Journal:  Oncotarget       Date:  2014-11-30

7.  Short-term treatment with taurolidine is associated with liver injury.

Authors:  René Fahrner; Anika Möller; Adrian T Press; Andreas Kortgen; Michael Kiehntopf; Falk Rauchfuss; Utz Settmacher; Alexander S Mosig
Journal:  BMC Pharmacol Toxicol       Date:  2017-08-11       Impact factor: 2.483

8.  FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Authors:  Agata Szymiczek; Sandra Pastorino; David Larson; Mika Tanji; Laura Pellegrini; Jiaming Xue; Shuangjing Li; Carlotta Giorgi; Paolo Pinton; Yasutaka Takinishi; Harvey I Pass; Hideki Furuya; Giovanni Gaudino; Andrea Napolitano; Michele Carbone; Haining Yang
Journal:  J Transl Med       Date:  2017-03-15       Impact factor: 5.531

9.  Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.

Authors:  M Buchholz; B Majchrzak-Stiller; S Hahn; D Vangala; R W Pfirrmann; W Uhl; C Braumann; A M Chromik
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

Review 10.  Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).

Authors:  Hanns Möhler; Rolf W Pfirrmann; Karl Frei
Journal:  Int J Oncol       Date:  2014-07-28       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.